Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2142743 | 0.93 | DUT (0.39) | DUT | |
| SCHEMBL1601699 | 0.88 | DUT (0.36) | DUT | |
| SCHEMBL7397926 | 0.80 | DUT (0.35) | DUT | |
| SCHEMBL28169884 | 0.79 | DUT (0.34) | DUT | |
| SCHEMBL12793189 | 0.77 | DUT (0.39) | DUT | |
| SCHEMBL28538333 | 0.76 | DUT (0.43) | DUT | |
| SCHEMBL8063404 | 0.76 | DUT (0.43) | DUT | |
| SCHEMBL852468 | 0.76 | DUT (0.40) | DUT | |
| SCHEMBL351046 | 0.75 | — | — | |
| SCHEMBL17891905 | 0.75 | DUT (0.32) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373932-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-23 | — | — | US | disclosed |
| US-20230373932-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-23 | — | — | US | disclosed |
| US-20210130300-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2021-05-06 | — | — | US | disclosed |
| EP-3744713-A1 | DIYHYDROPYRIMIDINE-2-ONE COMPOUNDS AND MEDICINAL USES THEREOF | Japan Tobacco Inc. (JP) | 2020-12-02 | — | — | EP | disclosed |
| CN-107001286-B | Dihydropyrimidine-2-one compounds and medicinal use thereof | 日本烟草产业株式会社 | 2020-07-07 | — | — | CN | disclosed |
| EP-3231793-B1 | DIHYDROPYRIMIDINE-2-ONE COMPOUNDS AND MEDICINAL USES THEREOF | JAPAN TOBACCO INC (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-10196363-B2 | Dihydropyrimidin-2-one compounds and medical use thereof | JAPAN TOBACCO INC. (JP) | 2019-02-05 | — | — | US | disclosed |
| EP-3231793-A1 | DIHYDROPYRIMIDINE-2-ONE COMPOUNDS AND MEDICINAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2017-10-18 | — | — | EP | disclosed |
| CN-107001286-A | The assimilation compound of dihydro-pyrimidin 2 and its medical usage | 日本烟草产业株式会社 | 2017-08-01 | — | — | CN | disclosed |
| US-20160194290-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2016-07-07 | — | — | US | disclosed |
| US-20030220503-A1 | Hydroxylation, carboxylation, cyclization, esterification, epoxidation, etherification | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-11-27 | — | — | US | disclosed |
| US-6617350-B2 | Sulfonamides which are aspartyl protease inhibitors; well suited for inhibiting HIV-1 and HIV-2 protease activity | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-09 | — | — | US | disclosed |
| US-6605726-B1 | Method for producing epothilone B and derivatives, and intermediate products for this method | SCHERING AG (DE) | 2003-08-12 | — | — | US | disclosed |
| EP-1121364-B1 | METHOD FOR PRODUCING EPOTHILONE B AND DERIVATIVES THEREOF | SCHERING AG (DE) | 2003-01-08 | — | — | EP | disclosed |
| US-20020198388-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2002-12-26 | — | — | US | disclosed |
| EP-1194404-A1 | INHIBITORS OF ASPARTYL PROTEASE | Vertex Pharmaceuticals Incorporated (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6319946-B1 | BENZODIOXOLYLSULFONAMIDES; INHIBITING HIV-1 AND HIV-2 PROTEASE ACTIVITY | VERTEX PHARMACEUTICALS INCORPORATED | 2001-11-20 | — | — | US | disclosed |
| EP-1121364-A1 | METHOD FOR PRODUCING EPOTHILONE B AND DERIVATIVES, AND INTERMEDIATE PRODUCTS FOR THIS METHOD | Schering Aktiengesellschaft (DE) | 2001-08-08 | — | — | EP | disclosed |
| WO-2000076961-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000023452-A1 | METHOD FOR PRODUCING EPOTHILONE B AND DERIVATIVES, AND INTERMEDIATE PRODUCTS FOR THIS METHOD | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196363-B2 | Dihydropyrimidin-2-one compounds and medical use thereof | REN, PKD2, ALPI | DUT 625/4885 |
| US-20020198388-A1 | Inhibitors of aspartyl protease | SPINT2, DNPEP, PRSS1 | DUT 702/4885 |
| US-20160194290-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | REN, PKD2, ALPI | DUT 625/4885 |
| US-20030220503-A1 | Hydroxylation, carboxylation, cyclization, esterification, epoxidation, etherification | CYP4A11, CYP4B1, CYP4F11 | DUT 2811/4885 |
| US-20210130300-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | REN, PKD2, ALPI | DUT 625/4885 |
| US-20230373932-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | REN, PKD2, ALPI | DUT 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.